# ATLANTIS (NCT02566993)

> Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02566993
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: PharmaMar
- Conditions: Small-cell Lung Cancer
- Interventions: Lurbinectedin (PM01183); Doxorubicin (DOX); Cyclophosphamide (CTX); Vincristine (VCR); Topotecan
- Enrollment: 613
- Primary outcome: Overall Survival (OS)

## Indexed commentary on ATLANTIS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=atlantis-nct02566993